Literature DB >> 15210759

A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors.

Yan-Ming Xu1, Li-Feng Wang, Lin-Tao Jia, Xiu-Chun Qiu, Jing Zhao, Cui-Juan Yu, Rui Zhang, Feng Zhu, Cheng-Ji Wang, Bo-Quan Jin, Si-Yi Chen, An-Gang Yang.   

Abstract

Clinical studies have suggested that human epidermal growth factor receptor-2 (HER2) provide a useful target for antitumor therapy. We previously described the generation of a chimeric HER2-targeted immunocasp-3 protein. In this study, we extend the repertoire of chimeric proapoptotic proteins with immunocasp-6, a construct that comprises a HER2-specific single-chain Ab, a single-chain Pseudomonas exotoxin A, and an active caspase-6, which can directly cleave lamin A leading to nucleus damage and inducing programmed cell death. We demonstrate that the secreted immunocasp-6 molecule selectively recognizes and induces apoptosis in HER2-overexpressing tumor cells in vitro, but not in cells with undetectable HER2. The immunocasp-6 gene was next transferred into BALB/c athymic mice bearing human breast SK-BR-3 tumors by i.m. injection of liposome-encapsulated vectors, by intratumor injection of adenoviral vectors, or by i.v. injection of PBMC modified by retroviral infection. Regardless of the method used, expression of immunocasp-6 suppressed tumor growth and prolonged animal survival significantly. Our data show that the chimeric immunocasp-6 molecule can recognize HER2-positive tumor cells, promptly attack their nucleus, and induce their apoptotic death, suggesting the potential of this strategy for the treatment of human cancers that overexpress HER2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210759     DOI: 10.4049/jimmunol.173.1.61

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  8 in total

Review 1.  Caspases: pharmacological manipulation of cell death.

Authors:  Inna N Lavrik; Alexander Golks; Peter H Krammer
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Folding and assembly kinetics of procaspase-3.

Authors:  Sara L Milam; A Clay Clark
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

Review 3.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Autophagy inhibition synergistically enhances anticancer efficacy of RAMBA, VN/12-1 in SKBR-3 cells, and tumor xenografts.

Authors:  Abhijit M Godbole; Puranik Purushottamachar; Marlena S Martin; Constantine Daskalakis; Vincent C O Njar
Journal:  Mol Cancer Ther       Date:  2012-02-14       Impact factor: 6.261

Review 5.  Targeting the apoptosis pathway in hematologic malignancies.

Authors:  Shadia Zaman; Rui Wang; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2014-02-04

Review 6.  Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases.

Authors:  Zhengqiu Zhou; Grant L Austin; Robert Shaffer; Dustin D Armstrong; Matthew S Gentry
Journal:  Trends Mol Med       Date:  2019-09-12       Impact factor: 11.951

7.  Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer.

Authors:  G Wang; J Qiu; R Wang; A Krause; J L Boyer; N R Hackett; R G Crystal
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

8.  SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.

Authors:  C Kimchi-Sarfaty; W D Vieira; D Dodds; A Sherman; R J Kreitman; S Shinar; M M Gottesman
Journal:  Cancer Gene Ther       Date:  2006-02-24       Impact factor: 5.854

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.